IP Library Granted Patent US 11,884,921
Granted Patent B2
US 11,884,921 · App. 18/078,821 · Granted Jan 30, 2024

Signal boost cascade assay

Inventors: Anurup Ganguli (San Diego, CA); Ashish Pandey (San Diego, CA); Ariana Mostafa (San Diego, CA); Jacob Berger (San Diego, CA)
Assignee: VedaBio, Inc.
C12N15/113C12N15/102C12N15/11C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,884,921
App. No.
18/078,821
Granted
Jan 30, 2024
Kind
B2
Abstract

The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods provide signal boost upon detection of target nucleic acids of interest in less than one minute and in some instances instantaneously at ambient temperatures down to 16° C. or less, without amplification of the target nucleic acids yet allowing for massive multiplexing, high accuracy and minimal non-specific signal generation.

Claims (43)

1. A method for preventing unwinding of blocked nucleic acid molecules in the presence of an RNP comprising the steps of:

providing blocked nucleic acid molecules;

providing ribonucleoprotein complexes comprising a Cas12a nucleic acid-guided nuclease that exhibits both cis- and trans-cleavage activity upon activation and a gRNA that recognizes an unblocked nucleic acid molecule resulting from trans-cleavage of the blocked nucleic acid molecules; and

engineering the nucleic acid-guided nuclease used in the ribonucleoprotein complex to result in a variant nucleic acid-guided nuclease where single stranded DNA is cleaved faster than double stranded DNA is cleaved.

2. The method of claim 1 , wherein the blocked nucleic acid molecules comprise a structure represented by any one of Formulas I-IV, wherein Formulas I-IV are in the 5′-to-3′ direction:

(a)A-(B-L) J -C-M-T-D  (Formula I);

wherein A is 0-15 nucleotides in length;

B is 4-12 nucleotides in length;

L is 3-25 nucleotides in length;

J is an integer between 1 and 10;

C is 4-15 nucleotides in length;

M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L) J -C and T-D are separate nucleic acid strands;

T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; and

D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A;

(b)D-T-T′-C-(L-B) J -A  (Formula II);

wherein D is 0-10 nucleotides in length;

T-T′ is 17-135 nucleotides in length;

T′ is 1-10 nucleotides in length and does not hybridize with T;

C is 4-15 nucleotides in length and comprises at least 50% sequence complementarity to T;

L is 3-25 nucleotides in length and does not hybridize with T;

B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;

J is an integer between 1 and 10;

A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

(c)T-D-M-A-(B-L) J -C  (Formula III);

wherein T is 17-135 nucleotides in length;

D is 0-10 nucleotides in length;

M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L) J -C are separate nucleic acid strands;

A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;

L is 3-25 nucleotides in length;

J is an integer between 1 and 10; and

C is 4-15 nucleotides in length; or

(d)T-D-M-A-L p -C  (Formula IV);

wherein T is 17-31 nucleotides in length (e.g., 17-100, 17-50, or 17-25);

D is 0-15 nucleotides in length;

M is 1-25 nucleotides in length;

A is 0-15 nucleotides in length and comprises a sequence complementary to D; and

L is 3-25 nucleotides in length;

p is 0 or 1;

C is 4-15 nucleotides in length and comprises a sequence complementary to T.

3. The method of claim 1 , wherein the RNP comprises a variant nucleic acid-guided nuclease comprising at least one mutation to the domains that interact with the PAM region or surrounding sequences on the blocked nucleic acid molecule and wherein the mutation is selected from mutations to amino acid residues K538, Y542 and K595 in relation to SEQ ID NO:1 and equivalent amino acid residues in orthologs.

4. The method of claim 3 , wherein there are at least two mutations to the domains that interact with the PAM region or surrounding sequences on the blocked nucleic acid molecules selected from mutations to amino acid residues K538, Y542 and K595 in relation to SEQ ID NO:1 and equivalent amino acid residues in orthologs.

5. The method of claim 4 , wherein there are at least three mutations to domains that interact with the PAM region or surrounding sequences on the blocked nucleic acid molecule selected from mutations to amino acid residues K538, Y542 and K595 in relation to SEQ ID NO:1 and equivalent amino acid residues in orthologs.

Assignments (2)
CHANGE OF NAME Recorded Aug 1, 2023
From: LABSIMPLY, INC.
To: VEDABIO, INC.
Reel/Frame 064462/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2022
From: GANGULI, ANURUP; PANDEY, ASHISH; MOSTAFA, ARIANA; BERGER, JACOB
To: LABSIMPLY, INC.
Reel/Frame 062194/0506 →
Continuity (5)
Provisional Application 63397785 · Aug 12, 2022
Provisional Application 63395394 · Aug 5, 2022
Provisional Application 63359183 · Jul 7, 2022
Provisional Application 63289112 · Dec 13, 2021
Related Publication 20230193273A1 · Jun 22, 2023
Cited By (1)
US 12,247,205